Technology

Innovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.

Adhering to new compliance legislation such as Identification of Medicinal Products (IDMP) can bring a pharma company benefits as well as challenges, writes Darren Cooper.

Scott Beauchamp discussed the future of analytics in the life sciences industry-and look at how peers in other industries have reaped the benefits of being early movers.

Rather than looking at what their peers are doing in digital health, pharma companies need to anticipate new challengers in the healthcare industry, writes Kal Patel.

This blog discusses the benefits of the pharma industry adopting the idea that media is data.

It is time for pharma companies to take a longitudinal view of their commercial efforts through digital maturity, writes Gaurav Kapoor.

Achieving proper security in industries like life sciences and healthcare, where web-based systems and internal networks are late in coming, may seem a daunting task. But it shouldn't be, writes Dr. JeffR. Livingstone.

Are the technologies and assumptions at the heart of healthcare AI trustworthy?

This article discusses real-time data capture and analytics in clinical trials.

Danish Gupta discuss the current strengths and weaknesses of artificial intelligence applications in life sciences.

Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.

mHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.

Tracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.

Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

William King offers five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

Sean McCarthy, President & CEO of CytomX, outlines the company’s journey from university startup to rising star of the immuno-oncology space.

In the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.

This article discusses the best practices for transforming legacy approaches of managing data into modern ones capable of achieving the ambitious visions of pharmaceutical companies.

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

Pharm Exec speaks to Prognos CEO Sundeep Bhan about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

Selecta Biosciences CEO Dr. Werner Cautreels talks about the company's innovative technology and how his entrepreneurial experiences in big pharma prepared him for the challenge of a new startup.

Today’s model requires a fourth partner-the systems integrator

Mastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.

Pharma companies today must increasingly provide evidence on real-world outcomes to differentiate and justify their products. But what is the true potential of real-world evidence studies and what are the right questions to ask in determining product performance in the marketplace?

In the second of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Extraction.